FDA approves new COPD drug from Verona Pharma

Lei Lei Wu

News Reporter

The FDA approved Verona Pharma’s drug for chronic obstructive pulmonary disease, or COPD, the first maintenance treatment with a new mechanism for the ailment in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA approves new COPD drug from Verona Pharma

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Why the Supreme Court's overrule of Chevron has major implications for the FDA

FDA rejects Rocket Pharma’s ultra-rare immune disease gene therapy over manufacturing

J&J details Phase 3 success of autoimmune disease drug, touting broader range than argenx’s Vyvgart

Biopharma leaders charting a path for the industry's LGBTQ+ community

Scientists unveil new way to make large changes to genes, and no CRISPR is required

Inside BARDA's multibillion-dollar effort to fund long-shot biotechs for Covid

FDA ap­proves new COPD drug from Verona Phar­ma

Lei Lei Wu

News Reporter

Sign up to read this article for free.

more like this

Why the Supreme Court's over­rule of Chevron has ma­jor im­pli­ca­tions for the FDA

FDA re­jects Rock­et Phar­ma’s ul­tra-rare im­mune dis­ease gene ther­a­py over man­u­fac­tur­ing

J&J de­tails Phase 3 suc­cess of au­toim­mune dis­ease drug, tout­ing broad­er range than ar­genx’s Vyv­gart

Bio­phar­ma lead­ers chart­ing a path for the in­dus­try's LGBTQ+ com­mu­ni­ty

Sci­en­tists un­veil new way to make large changes to genes, and no CRISPR is re­quired

In­side BAR­DA's multi­bil­lion-dol­lar ef­fort to fund long-shot biotechs for Covid

FDA approves new COPD drug from Verona Pharma

Why the Supreme Court's overrule of Chevron has major implications for the FDA

FDA rejects Rocket Pharma’s ultra-rare immune disease gene therapy over manufacturing

J&J details Phase 3 success of autoimmune disease drug, touting broader range than argenx’s Vyvgart

Biopharma leaders charting a path for the industry's LGBTQ+ community

Scientists unveil new way to make large changes to genes, and no CRISPR is required

Inside BARDA's multibillion-dollar effort to fund long-shot biotechs for Covid